Resources

This report, produced by IMS Health and commissioned by the Association of the British Pharmaceutical Industry (ABPI), provides information related to the uptake of Direct Acting Antiviral treatments (DAAs) over the last five years, to June 2016. The intention of the report is to benchmark the UK – in relation to patient access to these medicines – compared with other European countries. It finds that there have been significant variances in the ability of patients to access these medicines.

These Scottish guidelines, updated in January 2016, provide expert guidance to Health Boards, Area Drug and Therapeutics Committees, and treating clinicians on the efficacy of available treatments for hepatitis C. They also act as a clinical reference source for NHS National Procurement to produce rankings on cost-effectiveness. Development of the guidance was a collaboration between Scotland's viral hepatitis clinical leads and MCN co-ordinators network, National Services Scotland, and Healthcare Improvement Scotland.

On 13th December 2016, HCV Action and Public Health England (PHE) staged a hepatitis C good practice roadshow in Manchester. The event was designed to showcase and share best practice in the prevention, diagnosis, testing and treatment of hepatitis C, and identify specific issues and potential solutions for tackling hepatitis C in Manchester and the wider north west region.

This report provides an update on infectious diseases related to drug use in Europe for the period up to June 2016. It covers the most recent data both on infectious diseases among people who inject drugs in Europe, collected with the European Monitoring Centre for Drugs and Drug Addiction Drug-related infectious diseases (DRID) indicator, and on the responses in the area. It includes highlights and new findings discussed during the DRID indicator’s annual expert meeting, held in Lisbon on 6–8 June 2016.